Reply To: Cautious Investor — Market Weekly

#97931
Truman
Participant

AbbVie (ABBV 219.91, +3.42, +1.6%) and Apogee Therapeutics (APGE 133.13, +42.75, +47.3%) enter into a definitive agreement under which AbbVie will acquire Apogee for $135.11 per share in cash.